Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
AbbVie
Merck Sharp & Dohme LLC
British Columbia Cancer Agency
National Cancer Institute (NCI)